Successful trials in Africa of NmCV-5 vaccine open the door to affordable treatment for disease that kills 250,000 people a year
An effective, affordable meningitis vaccine has been successfully tested in Africa, raising hopes for the elimination of a disease that kills 250,000 people a year.
The NmCV-5 vaccine, developed by the Serum Institute of India and global health organisation Path, will protect against the five main meningococcal strains found in Africa, including the emerging X strain, for which there is currently no licensed injection.
Continue reading...